Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
EAAT2 CRISPR/Cas9 KO Plasmid (m): sc-422984
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EAAT2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the EAAT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: EAAT2 Antibody (E-1): sc-365634
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EAAT2 CRISPR/Cas9 KO Plasmid (m) | sc-422984 | 20 µg | $397.00 |
Overview
Slc1a2 encodes excitatory amino acid transporter 2 (EAAT2), a high-capacity Na+-dependent glutamate transporter predominantly expressed in astrocytes that clears synaptic glutamate to maintain excitatory neurotransmission and prevent excitotoxic stress. EAAT2 shapes glutamatergic signaling by coupling glutamate uptake to ionic gradients and supporting astrocyte–neuron metabolic coupling via the glutamate–glutamine cycle. Through regulation of extracellular glutamate homeostasis, Slc1a2 influences synaptic plasticity, neuronal survival, and network excitability. Altered EAAT2 function or expression has been linked to mechanisms relevant to neurodegeneration, epilepsy, and neuroinflammation, making Slc1a2 a common target in CNS pathway studies.
EAAT2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Slc1a2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Slc1a2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Slc1a2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish EAAT2 protein expression.
This CRISPR knockout system enables efficient generation of Slc1a2-deficient cell models for investigation of EAAT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Slc1a2 exon(s) critical for EAAT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Slc1a2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by EAAT2 CRISPR/Cas9 KO Plasmid (m) and EAAT2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Slc1a2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by EAAT2 HDR Plasmid (m) and EAAT2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Slc1a2 homology arms to support homology-directed repair at defined Slc1a2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.